COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Sigrid S. Skånland(Oslo University Hospital), Matthew R. Wilson(Beatson West of Scotland Cancer Centre), Lori A. Leslie(Hackensack University Medical Center), Susana Valenciano(Hospital Universitario Príncipe de Asturias), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Alan P Skarbnik(Novant Health), Javier López‐Jiménez(Hospital Universitario Ramón y Cajal), Talha Munir(Leeds Teaching Hospitals NHS Trust), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Craig A. Portell, Amanda N. Seddon(Rush University Medical Center), Fátima Mirás(Hospital Universitario 12 De Octubre), Harriet S. Walter(Leicester Royal Infirmary), John N. Allan(NewYork–Presbyterian Hospital), Guilherme Fleury Perini(Hospital Israelita Albert Einstein), Jeffrey J. Pu(SUNY Upstate Medical University), Scott F. Huntington(Yale University), Ryan Jacobs(Levine Cancer Institute), Nicolás Martínez‐Calle(Nottingham University Hospitals NHS Trust), Darko Antić(University of Belgrade), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Krista M. Isaac, Kerry A. Rogers(The Ohio State University), Helen Parry(University of Birmingham), Piers Patten, Erlene Seymour(Wayne State University), Anders Österborg(Karolinska University Hospital), Mazyar Shadman(University of Washington), Toby A. Eyre(Churchill Hospital), Inhye E. Ahn(National Institutes of Health), Paul M. Barr(Memorial Sloan Kettering Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Lotta Hansson(Karolinska Institutet), Alberto López‐García(Hospital Universitario Fundación Jiménez Díaz), Daniel Wojenski(Northwestern University), Raúl Córdoba(Hospital Universitario Fundación Jiménez Díaz), Alexander Coltoff(Columbia University Irving Medical Center), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Dima El‐Sharkawi(Royal Marsden Hospital), Sonia Lebowitz(Memorial Sloan Kettering Cancer Center), José A. García‐Marco(Hospital Universitario Puerta de Hierro Majadahonda), Peter O. Baker(Dana-Farber Cancer Institute), John M. Pagel, Manali Kamdar(University of Colorado Cancer Center), Angus Broom(Western General Hospital), Renata Walewska(Dorset HealthCare University NHS Foundation Trust)
Cited by 70
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k